> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# J&J's Talc Reserve Is Now About $9.0 Billion, And The Ovarian Deal Hinges On 95% Of Claims
- URL: https://www.bullished.co/j-and-js-talc-reserve-is-now-about-9-0-billion-and-the-ovarian-deal-hinges-on-95-of-claims-28570823/
- Published: 2026-10-21T21:22:21.000Z
- Updated: 2026-10-23T12:54:02.000Z
- Description: J&J's 10-Q puts the talc reserve at about $9.0 billion, with cash lower and Sail, bond and opioid bills also due.
- Author: Matteo Parrino
- Tags: SEC Filings, JNJ, Industry: Healthcare

[Johnson & Johnson](https://www.bullished.co/tag/jnj/)'s 10-Q, filed Wednesday, puts the talc reserve at [about $9.0 billion](https://www.sec.gov/Archives/edgar/data/0000200406/000020040626000197/jnj-20260927.htm?ref=bullished.co) as of the third quarter, up from roughly $3.7 billion in the [prior quarter's filing](https://www.sec.gov/Archives/edgar/data/0000200406/000020040626000153/jnj-20260628.htm?ref=bullished.co). The proposed ovarian-cancer settlement behind that jump is conditioned on participation by at least 95% of the remaining claims.

## The reserve and the condition attached to it

The filing describes the reserve as the present value of the ovarian settlement agreement, executed settlements, litigation defense and other costs. Approximately half of it is recorded as a current liability.

The ovarian plan calls for a $5.5 billion commitment by the company. The deal, struck with the firms steering the federal and state cases, takes effect only if "the express participation of at least 95 %" of the remaining claims is secured, among other conditions.

The filing says the company announced the plan in July, after favorable rulings in the federal multi-district litigation and plaintiffs' withdrawal of their causation experts in the first bellwether matters. The proposed agreement does not touch the mesothelioma docket, which remains ongoing.

As of September 27, about 76,500 plaintiffs in the United States have direct talc claims pending against the company and its affiliates.

## What it does to earnings and cash

The $5.5 billion charge sits in the quarter's results. Earnings before taxes were $34 million, against $7.5 billion a year earlier, and net earnings were $210 million, or $0.09 a share, versus $5.2 billion, or $2.12, according to the [10-Q](https://www.sec.gov/Archives/edgar/data/0000200406/000020040626000197/jnj-20260927.htm?ref=bullished.co). The earnings release of October 13 had already reported those figures.

Cash and cash equivalents stood at $16.9 billion, down from $19.7 billion at the end of fiscal 2025\. J&J's own list of near-term needs includes about $9.0 billion for talc, $3.2 billion for the current portion of corporate bonds, about $2.6 billion for the option to acquire Sail Biomedicines and about $0.9 billion for opioid settlements. The company says operating cash flow and access to borrowing will cover them; it has a $12.5 billion 364-day credit facility and can issue up to $20 billion of commercial paper.

J&J has paid Sail $0.8 billion upfront, including a $0.5 billion equity investment.

## Buybacks and the legacy of the bankruptcies

The filing's background on talc runs through restructurings and three Chapter 11 filings, each dismissed. J&J then reversed approximately $7.0 billion of reserves in the first quarter of 2025, and tort-system trials resumed.

The company reported repurchasing 6,543,070 shares in the third quarter at an average $261.16, against 970,250 shares at $229.54 in the second quarter. JNJ closed at $257.78 on Wednesday.

Two dates and one threshold matter next: whether claimants reach the 95% participation the $5.5 billion commitment requires, and October 30, 2026, when the relator in the REMICADE qui tam case must file any notice of appeal after losing summary judgment.

### Sources

- [10-Q Filing — Johnson & Johnson (JNJ)](https://www.sec.gov/Archives/edgar/data/0000200406/000020040626000197/jnj-20260927.htm?ref=bullished.co) — SEC EDGAR
- [10-Q Filing — Johnson & Johnson (JNJ), Q2 FY2026 filed 2026-07-23 (comparison basis)](https://www.sec.gov/Archives/edgar/data/0000200406/000020040626000153/jnj-20260628.htm?ref=bullished.co) — SEC EDGAR
- [Earnings release (8-K Item 2.02, a2026q3exhibit991.htm) — Johnson & Johnson, filed 2026-10-13](https://www.sec.gov/Archives/edgar/data/0000200406/000020040626000189/a2026q3exhibit991.htm?ref=bullished.co) — SEC EDGAR
- [Is Most-Watched Stock Johnson & Johnson (JNJ) Worth Betting on Now?](https://finance.yahoo.com/markets/stocks/articles/most-watched-stock-johnson-johnson-120005345.html?ref=bullished.co) — Yahoo Finance
- [Healthcare ETFs to Buy as JNJ Slips 6% Despite Q3 Earnings Beat](https://finance.yahoo.com/healthcare/articles/healthcare-etfs-buy-jnj-slips-124600612.html?ref=bullished.co) — Yahoo Finance
- [Johnson & Johnson (JNJ): Are Its Medical Device Deals Paying Off?](https://finance.yahoo.com/healthcare/articles/johnson-johnson-jnj-medical-device-163832582.html?ref=bullished.co) — Yahoo Finance
- [Is Johnson & Johnson (JNJ) Undervalued Following Its Latest Oncology Update?](https://finance.yahoo.com/healthcare/articles/johnson-johnson-jnj-undervalued-following-130926973.html?ref=bullished.co) — Yahoo Finance
- [Johnson & Johnson Announces 1-Yr Results From...](https://www.benzinga.com/news/26/10/62435772/johnson-johnson-announces-1-yr-results-phase-3-fuzion-study-showing-tremfya-maintained-or-improved-f?ref=bullished.co) — benzinga.com

### More on Johnson & Johnson

- [J&J's CFO Says Company Is 'Leaning Towards A Spin' Of DePuy Synthes, Targets Mid-2027](https://www.bullished.co/j-and-js-cfo-says-company-is-leaning-towards-a-spin-of-depuy-synthes-targets-mid-2027-7cc0f26f/)
- [J&J Net Earnings Fall 95.9% To $210 Million On Talc Plan, Deal Costs, Yet Raises 2026 Outlook](https://www.bullished.co/j-and-j-net-earnings-fall-95-9-to-210-million-on-talc-plan-deal-costs-yet-raises-2026-52a07733/)

[All Johnson & Johnson (JNJ) coverage →](https://www.bullished.co/tag/jnj/)